GH
Guardant Health, Inc.
September 14, 2026 · intraday
- Rarity
- 1.11
- Peak move
- +6.55%
- Float cap
- $19.8B
Guardant Health is a precision oncology company that provides blood and tissue tests, real-world data, and AI analytics for cancer care. Its products are used for early cancer screening, recurrence monitoring, and treatment selection, and are sold to oncologists, health systems, biopharmaceutical companies, and screening providers.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
7 events · 2 from SEC or newswire · 0 timed with the move- Key event
regulatory_approvalGuardant Health's Shield blood test for colorectal cancer screening will be covered under EviCore by Evernorth, the Cigna-owned benefits manager, clinical guidelines effective January 1, 2027, extending coverage across 23 states and lifting total covered Shield lives for ages 45+ to about 94 million.
insider_saleDirector Alex M Azar II exercised options on 1,651 shares of Guardant Health on September 12, 2026.
SEC4 0001402256-26-000004insider_saleGuardant Health Chief Information Officer Kumud Kalia sold 4,000 shares at $158.05 for $632,193 on September 11, 2026, leaving him 39,794 shares directly.
SEC4 0001927831-26-000022Webgurufocus.com- Key event
executive_remarkAt the Morgan Stanley 24th Annual Global Healthcare Conference, Guardant Health co-CEO AmirAli Talasaz and CFO Mike Bell discussed Shield's category scaling, cost per test declining from over $400 in Q2 toward $350 by year-end with a $200 long-term target, a sales force expanding toward 600-700 reps, and reiterated a 2028 biopharma revenue target of about $300 million.
- Key event
major_contractGuardant Health said its FDA-approved Shield blood test for colorectal cancer screening will be covered by Carelon Health Services, expanding access to roughly 90 million eligible U.S. patients aged 45 and older.
analyst_ratingUBS Group initiated coverage of Guardant Health with a buy rating and a $225 price target, implying 35.78% upside from the prior close.
litigation_outcomeA US court ordered Guardant Health to pay TwinStrand Biosciences and the University of Washington more than $245.2 million for willful infringement of two DNA-sequencing patents, plus a 6% royalty on US sales of 11 covered products through March 2033, and Guardant said it will appeal.